Evidence map›Paper›PMID 41357323›Full record

ArticleJournal of diabetes research2025

Artemether Attenuates High Glucose-Induced Inflammation and Fibrogenesis in Renal Tubular Epithelial Cells by Modulating the TGF-

Xiuli Zhang, Lingzhi Li, Rui Xue, Dan Liang, Yue Wang, Weidong Yang, Qinghui Zhou, Zhihong Chi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiuli ZhangDepartment of Nephrology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong Province, China.ORCID https://orcid.org/0000-0001-8123-8288
Lingzhi LiDepartment of Nephrology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong Province, China.
Rui XueDepartment of Nephrology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong Province, China.
Dan LiangRehabilitation Medicine Department, The 964 hospital of PLA, Changchun, Jilin Province, China.
Yue WangDepartment of Tissue Culture, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning Province, China.
Weidong YangDepartment of Nephrology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong Province, China.
Qinghui ZhouDepartment of Nephrology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong Province, China.
Zhihong ChiDepartment of Pathophysiology, China Medical University, Shenyang, Liaoning Province, China.ORCID https://orcid.org/0009-0005-1504-7842

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artemether (Art) is a derivative of artemisinin, originally sourced from traditional Chinese herbal medicine, with improved bioavailability, and is widely used for malaria treatment. Recently, its potential effects on diabetic complications, particularly diabetic kidney disease (DKD), have attracted increasing attention. This study aimed to evaluate the therapeutic effects of Art on DKD and to explore the underlying mechanisms. Specifically, we investigated the protective role of Art against high glucose (HG)-induced inflammatory biomarkers (transforming growth factor-

Indexed as

ArtemetherDiabetic NephropathiesEpithelial CellsGlucoseInflammationKidney TubulesKidney Tubules, ProximalPPAR gammaSmad ProteinsTransforming Growth Factor betaCell LineFibrosisHumansSignal TransductionTransforming Growth Factor beta1ArtemetherGlucosePPAR gammaPPARG protein, humanSmad ProteinsTransforming Growth Factor betaTransforming Growth Factor beta1artemetherdiabetic kidney diseasefibrosisinflammationTGF-β/Smad signaling pathway

Identifiers

PMID41357323
PMCPMC12681401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.